Search papers, labs, and topics across Lattice.
The paper introduces BrainHO, a novel method for learning hierarchical brain network organization from fMRI data for improved brain disorder diagnosis. BrainHO employs a hierarchical attention mechanism to aggregate nodes into a hierarchical structure based on intrinsic features, capturing complex connectivity patterns without relying on predefined sub-networks. By incorporating orthogonality and hierarchical consistency constraints, BrainHO achieves state-of-the-art classification performance on ABIDE and REST-meta-MDD datasets and identifies clinically relevant biomarkers.
Ditching predefined functional sub-networks unlocks state-of-the-art brain disorder diagnosis by learning hierarchical brain network organization directly from fMRI data.
Brain network analysis based on functional Magnetic Resonance Imaging (fMRI) is pivotal for diagnosing brain disorders. Existing approaches typically rely on predefined functional sub-networks to construct sub-network associations. However, we identified many cross-network interaction patterns with high Pearson correlations that this strict, prior-based organization fails to capture. To overcome this limitation, we propose the Brain Hierarchical Organization Learning (BrainHO) to learn inherently hierarchical brain network dependencies based on their intrinsic features rather than predefined sub-network labels. Specifically, we design a hierarchical attention mechanism that allows the model to aggregate nodes into a hierarchical organization, effectively capturing intricate connectivity patterns at the subgraph level. To ensure diverse, complementary, and stable organizations, we incorporate an orthogonality constraint loss, alongside a hierarchical consistency constraint strategy, to refine node-level features using high-level graph semantics. Extensive experiments on the publicly available ABIDE and REST-meta-MDD datasets demonstrate that BrainHO not only achieves state-of-the-art classification performance but also uncovers interpretable, clinically significant biomarkers by precisely localizing disease-related sub-networks.
